感染症
- 2 つの抗体を組み合わせた製剤 REGEN-COV と Covid-19 の外来患者における転帰REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
- 大規模医療組織における Covid-19 ワクチン接種後の心筋炎Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
- Covid-19 の高リスク外来患者に対する早期の回復者血漿Early Convalescent Plasma for High-Risk Outpatients with Covid-19
- SARS-CoV-2 中和抗体ソトロビマブによる Covid-19 の早期治療Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
- BNT162b2 mRNA Covid-19 ワクチンの 6 ヵ月間の安全性と有効性Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
- mRNA-1273 SARS-CoV-2 ワクチンの盲検期終了時点における有効性Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
- ワクチン起因性免疫性血小板減少症/血栓症の臨床像Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis
- Covid-19 ワクチン接種を完了した医療従事者におけるブレイクスルー感染Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
- 小児における細胞培養由来 4 価インフルエンザワクチンの有効性Efficacy of a Cell-Culture–Derived Quadrivalent Influenza Vaccine in Children
- 外来診療および入院診療の場における Covid-19 ワクチンの有効性Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings